These are data estimates from randomized trials, which tend to represent a best case scenario for a drug’s benefits. In addition, the Framingham database over-estimates CVD risk for some populations so these benefits are, if anything, a further overestimate. However, these estimates are based on five years of treatment, and the number of heart attacks and strokes often increases linearly over time. If true for any given individual this would mean that after ten years of treatment each of the NNT numbers would be halved, and halved again after 15 years, and so on.
It is also notable that not all drugs that lower BP lead to benefits. Atenolol, doxazosin, and aliskiren all lower blood pressure but large RCTs have shown no heart attack, stroke, or death benefit from these agents when used to lower blood pressure. Moreover, evidence for lowering BP below 150 (systolic) with any agent has not been beneficial in trials, but does increase harms (
see our other hypertension NNT review).
Importantly, the two earliest trials of blood pressure management treated patients whose average blood pressures were ~190/120 and 164/105 respectively, and demonstrated impressive and important benefits. These findings support data suggesting that the higher the blood pressure and the higher the risk, the better the NNT. This is evident in our numbers. Note, for instance, that our estimated overall NNTs (top of the page) are more favorable than the NNTs in Table 1. This is likely because patients in early thiazide trials were at higher risk, often due to existing heart disease. The Framingham calculator, which we used for calculations in Table 1, was developed for relatively healthy people and therefore assumes that patients have a lower risk at baseline than those in the thiazide trials.
Harms of BP medications are very real, but not as well documented in trials as benefits. Roughly 10% stop a drug due to intolerability (NNH* 10) and types of side effects vary between antihypertensive classes, including some that can be severe (angioedema, syncope, arrhythmias, electrolyte disturbances, etc.). Many of these side effects are dose related. Moreover, there is increasing documentation of a long held suspicion, namely that antihypertensives may increase fall risk and therefore risk of major injury, particularly for elderly patients. As always, in addition to side effects there is the inconvenience of, among many other issues, blood pressure measurement, dose and drug alterations, cost, and pill burden. These concerns are not addressed in trials but may impact quality of life in various ways and degrees.